TheSUBWAY.com Announces Investment Opinion on National Residential Properties, Inc., 24/7 Media Inc., Immune Response Corp., Palm Inc. and 3Com Corporation

Business Wire, June 4, 2001

Business Editors

NOTE TO EDITORS: The following is an investment opinion issued

by TheSUBWAY.com.

WESTON, Fla.--(BUSINESS WIRE)--June 4, 2001

TheSUBWAY.com releases the following investment opinions on National Residential Properties, Inc. (OTCBB:NRES), 24/7 Media Inc. (Nasdaq:TFSM), Immune Response Corp. (Nasdaq:IMNR), Palm Inc. (Nasdaq:PALM) and 3Com Corporation (Nasdaq:COMS).

National Residential Properties, Inc. (OTCBB:NRES) Previous Close Unchanged to .39 on volume 61,861,200 Shares: ACCUMULATE

National Residential Properties, Inc. (OTCBB:NRES) just announced that the company has started construction on the 2nd level of parking at the Conquistador Plaza Apts. (a 60 unit apartment building) and that the foundation for the perimeter wall is 100% complete and the steel is 100% complete for the perimeter wall around the basement. Furthermore, construction at Conquistador Plaza is one week ahead of schedule.

NRES also just announced that the company has signed a contract to sell it's interest in the joint venture with CT Adult Condominiums LLC. for $1,315,000. A $750,000 profit on this one deal.

NRES is new to TheSUBWAY.com and CRG is expecting great things from the company. CRG feels that NRES could be trading over .20 in the short term, with a 12 month target of .30 per share.

Keep an eye out for more interesting news on NRES to come.

24/7 Media Inc. (Nasdaq:TFSM) Previous Close: Down 14% to $0.42 on vol. 927,900 Shares: HOLD

24/7 Media Inc. (Nasdaq:TFSM), a global leader in multi-platform interactive marketing, has issued improved loss per share guidance for the second quarter. The announcement follows the sale of 24/7 Exactis to Experian, which closed last week. With the sale of Sabela Media, Award Track, and 24/7 Exactis, 24/7 Media has received gross proceeds of more than $19 million and has eliminated more than $20 million in annualized cash outflow. Overall, 24/7 Media has reduced its annualized operating expenses by approximately $65 million since it began its strategic operating plan in November 2000.

According to TFSM and as a result of the divestitures, 24/7 Media announced a forecasted 20 percent improvement in loss per share for the second quarter compared with the first quarter. This upwardly revises previous guidance of a 10 to 15 percent improvement over the actual loss per share of $0.58 reported at the end of the first quarter. Revenues for the second quarter are now projected in the range of $18 million and $21 million, compared with the $22 million to $25 million range previously expected. This reduction in revenue is a direct result of the removal of Exactis and Sabela revenues.

'As we have stated before, 24/7 Media continues to aggressively build cash reserves, streamline operations and reduce our operating expenses,' said David Moore, CEO of 24/7 Media. 'We are also evaluating the additional divestitures of our broadband and professional services division and our European division, both of which now fall outside of our strategic focus on our core group of products, expertise and markets. We have received strong interest in each property and hope to conclude one or more transactions in the third quarter.'

Immune Response Corp. (Nasdaq:IMNR) Previous Close: Down 55% to $2.18 on vol. 8,369,600 Shares: HOLD

Immune Response Corp. (Nasdaq:IMNR) announced that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-based therapy.

According to IMNR, the results indicated that the study did not meet the primary endpoint (i.e. time to increase to 5,000 copies/ml of viral load -- the amount of HIV detected in the blood -- or a 50% decrease in CD4 T cells/ml or a decrease to less than 250 CD4 T cells/ml while on antiretroviral therapy (ART)). The primary endpoint analysis revealed no significant difference between the control group 41% (50/121) and the REMUNE group 30% (35/118) p=0.20.

The DSMB also noted however, that their study included a subgroup analysis that seemed to indicate that REMUNE may have had a positive effect on viral load in patients that are more immunocompetent. The DSMB recommended further studies with REMUNE in such patients.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

Palm, Inc. (Nasdaq:PALM) Previous Close: Up 10% to $6.19 on vol. 21,926,100 Shares: ACCUMULATE

Palm, Inc. (Nasdaq:PALM), a pioneer in the field of mobile and wireless Internet solutions and a leading provider of handheld solutions, announced it has hired Todd Bradley, formerly executive vice president of global operations at Gateway Inc., to be executive vice president and chief operating officer for the Solutions Group. In addition, the company said channel sell-through has continued to improve as the company's new line -- the m500 series -- is selling well in the United States and has just begun selling internationally.